Immune mediation of pancytopenia in myelodysplastic syndromes: Pathophysiology and treatment

The Myelodysplastic Syndromes: Pathobiology and Clinical Management

Volumn , Issue , 2002, Pages 373-398

  Young, Neal S ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4444280649     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (129)

1. Yoshida Y, Mufti GJ. Apoptosis and its significance in MDS: controversies revisited. Leuk Res 1999; 23:777-785.
2. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998; 101:220-230.
3. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14:2-8.
4. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22:1123-1136.
5. Young NS. Aplastic anaemia. Lancet 1995; 346:228-232.
6. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336:1365-1372.
7. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000; 37:3-14.
8. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91:612-617.
9. Imashuku S, Kitazawa K, Ishii M, Kataoka S, Asami K, Ishii E, Fukushima K, Sako M, Matsubayashi T, Teramura GT, Hibi S. Bone marrow changes mimicking myelodysplasia in patients with hemophagocytic lymphohistiocytosis. Int J Hema-tol 2000; 72:353-357.
10. Geary CG, Marsh JC, Gordon-Smith EC. Hypoplastic myelodysplasia (MDS). Br J Haematol 1996; 94:582-583.
11. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van’t Veer-Korthof E, Gluckman E. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329:1152-1157.
12. Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, Bregante S, Valeriani A, Mordini N, Lamparelli T, Gualandi F, Occhini D, Baciga-lupo A. Cytogenetic abnormalities in patients with severe aplastic anemia. Haema-tologica 1996; 81:418-422.
13. Raza A, Alvi S, Borok RZ, Span L, Parcharidou A, Alston D, Rifkin S, Robin E, Shah R, Gregory SA. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leuk Lymphoma 1997; 27:111-118.
14. Bincoletto C, Saad ST, Soares da Silva E, Queiroz ML. Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome. Br J Cancer 1998; 78:621-624.
15. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000; 110:584-590.
16. Ruutu T, Partanen S, Lintula R, Teerenhovi L, Knuutila S. Erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Scand J Haematol 1984; 32:395-402.
17. Maciejewski JP, Kim S, Sloand E, Selleri C, Young NS. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am J Hematol 2000; 65:123-131.
18. Dan K, An E, Futaki M, Inokuchi K, Gomi S, Yamada T, Ogata K, Tanabe Y, Ohki I, Shinohara T, et al. Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Haematol 1993; 89:113-118.
19. Fukushima Y, Kanno Y, Miura AB. Three-lineage hemopoietic precursor cells and effectiveness of recombinant human erythropoietin in patients with myelodysplastic syndromes. Tohoku J Exp Med 1992; 166:375-385.
20. Juvonen E, Partanen S, Knuutila S, Ruutu T. Megakaryocyte colony formation by bone marrow progenitors in myelodysplastic syndromes. Br J Haematol 1986; 63: 331-334.
21. Juvonen E, Partanen S, Knuutila S, Ruutu T. Colony formation by megakaryocyte progenitors in myelodysplastic syndromes. Eur J Haematol 1989; 42:389-395.
22. Juvonen E, Aimolahati A, Volin L, Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocytic progenitors in myelodysplastic syndromes. Leuk Res 1999; 23:889-894.
23. Geissler D, Zwierzina H, Pechlaner C, Gaggl S, Schmalzl F, Konwalinka G, Braunsteiner H. Abnormal megakaryopoiesis in patients with myelodysplastic syndromes: analysis of cellular and humoral defects. Br J Haematol 1989; 73:29-35.
24. Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1988 Aug; 16(7):594-602.
25. Carlo-Stella C, Cazzola M, Bernasconi P, Bergamaschi G, Dezza L, Pedrazzoli P, Rosti V, Tomaselli S, Zappone E. In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes. Haematologica 1989; 74:181-186.
26. Maciejweski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood 1996; 88:1983-1991.
27. Backx B, Broeders L, Touw I, Lowenberg B. Blast colony-forming cells in myelo-dysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 1993; 7:75-79.
28. Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H, Koizumi K, Yasukouchi T, Yamaguchi M, Koike T. Proliferation and differentiation of myelo-dysplastic CD34+ cells: phenotypic subpopulation of marrow CD34+ cells. Blood 1995; 85:194-202.
29. Maciejewski JP, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994; 87:227-234.
30. Schouten HC, Delwel R, Bot FJ, Hagemeijer A, Touw IP, Lowenberg B. Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes. Leuk Res 1989; 13:245-251.
31. Shihab-el-Deen A, Guevara C, Prchal JF. Bone marrow cultures in dysmyelopoie-tic syndrome: diagnostic and prognistic evaluation. Acta Haematol 1987; 78:17-22.
32. Mayani H, Baines P, Bowen DT, Jacobs A. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia 1989; 3:29-32.
33. Baines P, Bowen D, Jacobs A. Clonal growth of haematopoietic progenitor cells from myelodysplastic marrow in response to recombinant haemopoietins. Leuk Res 1990; 14:247-253.
34. Nagler A, MacKichan ML, Negrin RS, Donlon T, Greenberg PL. Effects of granulocyte colony-stimulating factor therapy on in vitro hemopoiesis in myelodysplastic syndromes. Leukemia 1995; 9:30-39.
35. Merchav S, Nielson OJ, Rosenbaum H, Sharon R, Brenner B, Tatarsky I, Scigalla P, Wieczorek L. In vitro studies of erythropoietin-dependent regulation of erythro-poiesis in myelodysplastic syndromes. Leukemia 1990; 4:771-774.
36. Carlo-Stella C, Cazzola M, Bergamaschi G, Bernasconi P, Dezza L, Invernizzi R, Pedrazzoli P. Growth of human hematopoietic colonies from patients with myelo-dysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. Leukemia 1989; 3:363-366.
37. Nagler A, Binet C, MacKichan ML, Negrin R, Bangs C, Donlon T, Greenberg P. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood 1990; 76: 1299-1307.
38. Soligo D, Servida F, Cortelezzi A, Pedretti D, Uziel L, Morgutti M, Pogliani E, Lambertenghi Deliliers G. Effects of recombinant human stem cell factor (rh-SCF) on colony formation and long-term bone marrow cultures (LTBMC) in patients with myelodysplastic syndromes. Eur J Haematol 1994; 52:53-60.
39. Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodys-plastic syndromes. Leukemia 1994; 8:833-838.
40. Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haematopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 1990; 75:16-25.
41. Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H, Nabeshima R, Shima D, Handa H, Toyama K. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999; 23:239-246.
42. Novitzky N, Mohamed R, Finlayson J, du Toit C. Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000; 28:941-949.
43. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia, the correlate of ineffective hematopoiesis. Leuk Lymphoma 1990; 2: 415-418.
44. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Col-ovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11:656-659.
45. Shetty V, Hussaini S, Broady-Robinson L, Allampallam K, Mundle S, Borok R, Broderick E, Mazzoran L, Zorat F, Raza A. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000; 96: 1388-1392.
46. Ohmori M, Ohmori S, Ueda Y, Yoshida Y, Okuda M. Ineffective hematopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. Int J Cell Cloning 1990; 9:521-530.
47. Anzai N, Kawabata H, Hirama T, Masutani H, Ohmori M, Yoshida Y, Okuma M. Marked apoptosis of human myelomonocytic leukemia cell line P39: significance of cellular differentiation. Leukemia 1994; 8:446-453.
48. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 1996; 95:368-371.
49. Parcharidou A, Raza A, Economopoulos T, Papageorgiou ES, Anagnostou D, Papa-daki T, Raptis S. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur J Haematol 1999; 62:19-26.
50. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 2000; 102:115-123.
51. Cortelezzi A, Di Stefano M, Sarina B, Giannini S, Pomas M, Silvestris L, et al. Apoptosis in myelodysplastic syndromes (MDS): putative role of the bcl2 protooncogene. Blood 1996; 88:95a.
52. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 1998; 22:767-777.
53. Mundle SD, Reza S, Ali A, Mativi BY, Shetty V, Venugopal P, Gregory SA, Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140:201-207.
54. Hellström-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997; 21:415-425.
55. Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S, Mativi BY, Allampallam K, Ali A, Venugopal P, Gezer S, Broady-Robinson L, Cartlidge J, Showel M, Hussaini S, Ragasa D, Ali I, Chaudhry A, Waggoner S, Lisak L, Huang RW, Raza A. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol 1999; 62:90-94.
56. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11:839-845.
57. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88:4275-4287.
58. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96:3932-3938.
59. Ricciardi MR, Petrucci MT, Ariola C, Gregorj F, Mazzola F. High levels of apoptosis characterize RAEB and are lost during leukemic transformation. Blood 1998; 90:520a.
60. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996; 63:265-278.
61. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-276.
62. Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genes. Leukemia 1999; 13:1554-1563.
63. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H, Rose S, Mativi BY, Gregory SA, Preisler HD, Raza A. The relative extent and propensity of CD34+ vs. CD34— cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999; 69:152-159.
64. Laveder F, Marcolongo R. Uncontrolled triggering of programmed cell death (apoptosis) in haematopoietic stem cells: a new hypothesis for the pathogenesis of aplastic anaemia. Immunol Cell Biol 1996; 74:159-162.
65. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S, Preisler H. A paradigm shift in myelodysplastic syndromes. Leukemia 1996; 10:1648-1652.
66. Koike M, Ishiyama T, Tomoyasu S, Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 1995; 19:639-644.
67. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma by bone marrow cells from patients with myelo-dysplastic syndromes. Leukemia 1997; 11:2049-2054.
68. Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H. Detection of TNF alpha expression in the bone marrow and determination of TNF alpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res 2000; 6:18-23.
69. [Deleted in proof.]
70. Allampallam K, Shetty V, Hussaini S, Mazzoran L, Zorat F, Huang R, Raza A. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res 1999; 19:5323-5328.
71. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6:1268-1272.
72. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and FasLigand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103:176-188.
73. Reza S, Shetty V, Dar S, Qawi H, Raza A. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 1998; 18:871-877.
74. Hofmann WK, Seipelt G, Ottmann OG, Kalina U, Koschmieder S, Brucher J, Frickhofen N, Klausmann M, Mitrou PS, Hoelzer D. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 2000; 79: 255-258.
75. Shinohara K, Muraki K, Ota I, Nawata R, Oeda E, Takahashi T. Increased levels of soluble tumor necrosis factor receptors in patients with aplastic anemia and my-elodysplastic syndrome. Am J Hematol 2000; 65:326-327.
76. Kitagawa M, Takahashi M, Yamaguchi S, Inoue M, Ogawa S, Hirokawa K, Kamiy-ama R. Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. Leukemia 1999; 13:699-703.
77. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997; 99:625-631.
78. Reza S, Dar S, Andric T, Qawi H, Mundle S, Shetty V, Venugopal P, Ali I, Lisak L, Raza A. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk Lymphoma 1999; 33:281-287.
79. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, Gooley T. Negative regulators of hemopoiesis and stroma function in patients with myelo-dysplastic syndrome. Leuk Lymphoma 2000; 37:405-414.
80. Ohmori M, Ohmori S, Ueda Y, Tohyama K, Yoshida Y, Uchino H. Myelodysplastic syndrome (MDS)-associated inhibitory activity on haemopoietic progenitor cells. Br J Haematol 1990; 74:179-184.
81. Kerndrup G, Hokland P. Natural killer cell-mediated inhibition of bone marrow colony formation (CFU-GM) in refractory anaemia (preleukaemia): evidence for patient-specific cell populations. Br J Haematol 1988; 69:457-462.
82. Aizawa S, Hiramoto M, Hoshi H, Toyama K, Shima D, Handa H. Establishment of stromal cell line from an MDS RA patient which induced an apoptotic change in hematopoietic and leukemic cells in vitro. Exp Hematol 2000; 28:148-155.
83. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322.
84. Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U, Reza S, Cartlidge JD, Venugopal P, Shetty V, Gregory SA, Robin E, Rifkin S, Shah R, Raza A. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999; 70: 83-90.
85. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12:486-492.
86. Lepelley P, Grardel N, Emy O, Iaru T, Obein V, Cosson A, Fenaux P. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma 1998; 30: 307-312.
87. Won JH, Yu BW, Hong DS, Suh WS, Jeon JW, Baick SH, et al. The expression of the Fas antigen and apoptosis in patients with myelodysplastic syndromes and its clinical relevance. Blood 1996; 88:95a.
88. Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999; 13:44-53.
89. Porzsolt F, Heimpel H. Impaired T-cell and NK-cell function in patients with preleukemia. Blut 1982; 45:243-248.
90. Anderson RW, Volsky DJ, Greenberg B, Knox SJ, Bechtold T, Kuszynski C, Har-ada S, Purtilo DT. Lymphocyte abnormalities in preleukemia. 1. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res 1983; 7:389-395.
91. Takagi S, Kitagawa S, Takeda A, Minato N, Takaku F, Miura Y. Natural killerinterferon system in patients with preleukaemic states. Br J Haematol 1984; 58: 71-81.
92. Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res 1984; 8:239-247.
93. Okabe M, Minagawa T, Nakane A, Sakurada K, Miyasaki T. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodys-plastic syndromes. Scand J Haematol 1986; 37:111-117.
94. Janowska-Wieczorek A, Jakobisiak M, Dobaczewska H. Decreased antibody-dependent cellular cytotoxicity in preleukemic syndromes. Acta Haematol 1983; 69:132-135.
95. Baumann MA, Milson TJ, Patrick CW, Libnoch JA, Keller RH. Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol 1986; 22:17-26.
96. Colombat PH, Renoux M, Lamagnere JP, Renoux G. Immunologic indices in my-elodysplastic syndromes. Cancer 1988; 61:1075-1081.
97. Bynoe AG, Scott CS, Ford P, Roberts BE. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol 1983; 54:97-102.
98. Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H, Tamura A, Fujimori Y, Takemoto Y, Kanamaru A, Kakishita E. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hema-tol 1997; 66:345-351.
99. Economopoulos T, Economidou J, Giannopoulos G, Terzoglou C, Papageorgiou E, Dervenoulas J, Arseni P, Hadjioannou J, Raptis S. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 1985; 38:908-911.
100. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63:143-147.
101. Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989; 42:1088-1091.
102. Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:571-586.
103. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995; 91:403-408.
104. Copplestone JA, Mufti GJ, Hamblin TJ, Oscier DG. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy. Br J Haematol 1986; 63:149-159.
105. Katsuki K, Shinohara K, Kameda N, Yamada T, Takeda K, Kamei T. Two cases of myelodysplastic syndrome with extramedullary polyclonal plasma cell proliferation and autoantibody production: possible role of soluble Fas antigen for production of excessive self-reactive B cells. Intern Med 1998; 37:973-977.
106. Shiozawa S, Ogawa R, Morimoto I, Tanaka Y, Kanda N, Tatsumi E, Yamaguchi N, Fujita T. Polyarthritis, mononeuritis multiplex and eczematous ulcerative skin rash in a patient with myelodysplastic syndrome and peripheral large granular lymphocytosis. Clin Exp Rheumatol 1991; 9:629-633.
107. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorb-ara L, Young NS, Barrett AJ. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001; 112:195-200.
108. Bagby GC Jr, Gabourel JD, Linman JW. Gluticocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med 1980; 92:55-58.
109. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988; 68:139-140.
110. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79:1548-1551.
111. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699-705.
112. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088.
113. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322.
114. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, Hochova I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 200:304-309.
115. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Bel-pomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-2112.
116. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996; 23(4 suppl):58-63.
117. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90:3364-3369.
118. List AF, Holmes H, Greenberg PL, Bennett JM, Oster W. Phase II study of amifostine in patients with myelodysplastic syndromes. Blood 1999; 94(suppl 1):305a.
119. Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang RW, Venugopal P, Gezer S, Gregory SA, Hsu WT, Loew J, Robin E, Rifkin S, Shah R, Divgi A, Taylor R, Grosset A. Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients’ malignancy. Hematology 2000; 5:275-284.
120. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu WT, Huang RW. Patients with myelo-dysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95:1580-1587.
121. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol 1995; 18:189-193.
122. Raza A, Allampallam K, Shetty V, Mundle S, Borok R, Lisak L et al. Biologic and clinical response to recombinant human soluble tumor necrosis factor receptor (Enbrel) in patients with myelodysplastic syndromes. Blood 1999; 94(suppl 1): 171a.
123. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99:160-167.
124. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocyte. J Exp Med 1991; 173:699-703.
125. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81:219-223.
126. Amato RJ, Loughnan MSFE, Folkman J. Thalidomide is an inhibitor of angiogen-esis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
127. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000; 50:229-235.
128. Barrett AJ, Saunthararajah Y. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37:15-29.
129. Maciejewski JP, Risitano AM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002; in press.